Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway

3 days ago 7

Maham Fatima

Sun, March 8, 2026 astatine 11:57 AM CDT 2 min read

Prime Medicine Inc. (NASDAQ:PRME) is 1 of the best caller penny stocks to buy. On March 3, Prime Medicine reported its full-year 2025 fiscal results, highlighting a displacement toward its successful vivo liver franchise. The institution ended the twelvemonth with $191.4 cardinal successful cash, currency equivalents, and investments, providing a fiscal runway into 2027. Despite a nett nonaccomplishment of $201.1 cardinal for the year, R&D expenses remained comparatively unchangeable astatine $160.6 cardinal arsenic the institution optimized its workforce and deprioritized its Chronic Granulomatous Disease/CGD programme to absorption connected high-priority objective milestones.

The institution is advancing toward cardinal regulatory filings for its pb liver-focused programs successful Wilson Disease/WD and Alpha-1 Antitrypsin Deficiency/AATD. Prime Medicine remains connected way to taxable an IND oregon CTA for the WD programme successful H1 2026, followed by a mid-2026 submission for the AATD program. Initial objective information for some indications are expected successful 2027. Additionally, the institution is progressing its Cystic Fibrosis programme with enactment from the Cystic Fibrosis Foundation and continues its CAR-T concern with Bristol Myers Squibb.

Prime Medicine (PRME) Focuses connected Liver Franchise With $191.4M Cash Runway

Photo by RephiLe h2o connected Unsplash

Regarding its CGD candidate, PM359, Prime Medicine Inc. (NASDAQ:PRME) is actively engaging with the FDA to prosecute an accelerated support pathway. This follows the work of affirmative Phase 1/2 information successful the New England Journal of Medicine, which showed durable restoration of enzyme enactment and aboriginal objective benefits. The institution intends to taxable a BLA erstwhile last alignment with the FDA is reached, perchance making PM359 the archetypal Prime Edited therapy disposable to patients.

Prime Medicine Inc. (NASDAQ:PRME) is simply a biotechnology institution that delivers familial medicines to code the spectrum of diseases by deploying cistron editing exertion successful the US.

While we admit the imaginable of PRME arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and Goldman Sachs Value Stocks: 10 Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article